EP4132980A1 - Chitosan-based beads, and preparation, compositions and uses thereof - Google Patents
Chitosan-based beads, and preparation, compositions and uses thereofInfo
- Publication number
- EP4132980A1 EP4132980A1 EP21806782.5A EP21806782A EP4132980A1 EP 4132980 A1 EP4132980 A1 EP 4132980A1 EP 21806782 A EP21806782 A EP 21806782A EP 4132980 A1 EP4132980 A1 EP 4132980A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- beads
- chitosan
- composition
- carboxyalkyl
- carboxyalkyl chitosan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011324 bead Substances 0.000 title claims abstract description 300
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 235
- 239000000203 mixture Substances 0.000 title claims abstract description 148
- 238000002360 preparation method Methods 0.000 title claims description 25
- -1 and preparation Substances 0.000 title description 6
- 125000004181 carboxyalkyl group Chemical group 0.000 claims abstract description 145
- 239000000017 hydrogel Substances 0.000 claims abstract description 116
- 238000000034 method Methods 0.000 claims abstract description 92
- 229920000642 polymer Polymers 0.000 claims abstract description 79
- 239000011159 matrix material Substances 0.000 claims abstract description 39
- 239000008346 aqueous phase Substances 0.000 claims abstract description 24
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims abstract description 23
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 22
- 238000002347 injection Methods 0.000 claims description 63
- 239000007924 injection Substances 0.000 claims description 63
- 239000000243 solution Substances 0.000 claims description 53
- 229920002674 hyaluronan Polymers 0.000 claims description 52
- 210000001519 tissue Anatomy 0.000 claims description 52
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 36
- 239000003431 cross linking reagent Substances 0.000 claims description 35
- 229940099552 hyaluronan Drugs 0.000 claims description 34
- 238000004132 cross linking Methods 0.000 claims description 33
- 239000012071 phase Substances 0.000 claims description 29
- 241001465754 Metazoa Species 0.000 claims description 28
- 238000006640 acetylation reaction Methods 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 25
- 230000021736 acetylation Effects 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 230000015271 coagulation Effects 0.000 claims description 23
- 238000005345 coagulation Methods 0.000 claims description 23
- 238000006467 substitution reaction Methods 0.000 claims description 23
- 238000002513 implantation Methods 0.000 claims description 22
- 239000013543 active substance Substances 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 18
- 210000000845 cartilage Anatomy 0.000 claims description 17
- 238000011049 filling Methods 0.000 claims description 17
- 238000005406 washing Methods 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- 230000008439 repair process Effects 0.000 claims description 14
- 241000282412 Homo Species 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 229920001222 biopolymer Polymers 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 238000000746 purification Methods 0.000 claims description 11
- 229920001282 polysaccharide Polymers 0.000 claims description 10
- 150000004676 glycans Chemical class 0.000 claims description 9
- 239000005017 polysaccharide Substances 0.000 claims description 9
- 230000007547 defect Effects 0.000 claims description 7
- 239000007790 solid phase Substances 0.000 claims description 7
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 claims description 6
- 239000013060 biological fluid Substances 0.000 claims description 6
- 210000004207 dermis Anatomy 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 238000011200 topical administration Methods 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000003047 N-acetyl group Chemical group 0.000 claims description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 4
- 210000001508 eye Anatomy 0.000 claims description 4
- 239000007943 implant Substances 0.000 claims description 4
- 210000003041 ligament Anatomy 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 210000002435 tendon Anatomy 0.000 claims description 4
- QWVCIORZLNBIIC-UHFFFAOYSA-N 2,3-dibromopropan-1-ol Chemical compound OCC(Br)CBr QWVCIORZLNBIIC-UHFFFAOYSA-N 0.000 claims description 3
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 claims description 3
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 3
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 claims description 3
- 210000001503 joint Anatomy 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 210000001179 synovial fluid Anatomy 0.000 claims description 3
- 210000001258 synovial membrane Anatomy 0.000 claims description 3
- OSXSWVHSLRHTHZ-UHFFFAOYSA-N 2,4-dibromobutan-1-ol Chemical compound OCC(Br)CCBr OSXSWVHSLRHTHZ-UHFFFAOYSA-N 0.000 claims description 2
- OCMDEHWOXQGQOZ-UHFFFAOYSA-N 2,5-dibromopentan-1-ol Chemical compound OCC(Br)CCCBr OCMDEHWOXQGQOZ-UHFFFAOYSA-N 0.000 claims description 2
- ZKODPGZNBMIZFX-UHFFFAOYSA-N 2-(2-bromoethyl)oxirane Chemical compound BrCCC1CO1 ZKODPGZNBMIZFX-UHFFFAOYSA-N 0.000 claims description 2
- ZRRZAIJKJYIGIV-UHFFFAOYSA-N 2-(3-bromopropyl)oxirane Chemical compound BrCCCC1CO1 ZRRZAIJKJYIGIV-UHFFFAOYSA-N 0.000 claims description 2
- PTPMSMVSPQLTOU-UHFFFAOYSA-N 2-(3-bromopropyl)thiirane Chemical compound BrCCCC1CS1 PTPMSMVSPQLTOU-UHFFFAOYSA-N 0.000 claims description 2
- VTFRCOGCPHVIHW-UHFFFAOYSA-N 2-(bromomethyl)thiirane Chemical compound BrCC1CS1 VTFRCOGCPHVIHW-UHFFFAOYSA-N 0.000 claims description 2
- 235000012754 curcumin Nutrition 0.000 claims description 2
- 229940109262 curcumin Drugs 0.000 claims description 2
- 239000004148 curcumin Substances 0.000 claims description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 2
- 229940102213 injectable suspension Drugs 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000001294 propane Substances 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 claims description 2
- 210000001260 vocal cord Anatomy 0.000 claims description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims 1
- PXESMAOTBGZAIZ-UHFFFAOYSA-N 2,5-dibromopentane-1-thiol Chemical compound SCC(Br)CCCBr PXESMAOTBGZAIZ-UHFFFAOYSA-N 0.000 claims 1
- XRWMHJJHPQTTLQ-UHFFFAOYSA-N 2-(chloromethyl)thiirane Chemical compound ClCC1CS1 XRWMHJJHPQTTLQ-UHFFFAOYSA-N 0.000 claims 1
- ISCMYZGMRHODRP-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCN=C=N ISCMYZGMRHODRP-UHFFFAOYSA-N 0.000 claims 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims 1
- 239000001263 FEMA 3042 Substances 0.000 claims 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 claims 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims 1
- 206010072170 Skin wound Diseases 0.000 claims 1
- 125000005442 diisocyanate group Chemical group 0.000 claims 1
- 229940030275 epigallocatechin gallate Drugs 0.000 claims 1
- 235000004515 gallic acid Nutrition 0.000 claims 1
- 229940074391 gallic acid Drugs 0.000 claims 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 claims 1
- 229920002258 tannic acid Polymers 0.000 claims 1
- 235000015523 tannic acid Nutrition 0.000 claims 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims 1
- 229940033123 tannic acid Drugs 0.000 claims 1
- 239000000047 product Substances 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- HPILSDOMLLYBQF-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COC(CCC)OCC1CO1 HPILSDOMLLYBQF-UHFFFAOYSA-N 0.000 description 28
- 239000000725 suspension Substances 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 229960005294 triamcinolone Drugs 0.000 description 26
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical group O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 26
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 20
- 238000009472 formulation Methods 0.000 description 20
- 210000003491 skin Anatomy 0.000 description 18
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 17
- 229960003160 hyaluronic acid Drugs 0.000 description 17
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical group N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 238000007906 compression Methods 0.000 description 11
- 230000006835 compression Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 235000010323 ascorbic acid Nutrition 0.000 description 10
- 229960005070 ascorbic acid Drugs 0.000 description 10
- 239000011668 ascorbic acid Substances 0.000 description 10
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Chemical group NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 10
- 239000001110 calcium chloride Substances 0.000 description 10
- 229910001628 calcium chloride Inorganic materials 0.000 description 10
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000004005 microsphere Substances 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 10
- 208000005422 Foreign-Body reaction Diseases 0.000 description 9
- 239000012736 aqueous medium Substances 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 229920002101 Chitin Polymers 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000002538 fungal effect Effects 0.000 description 7
- 238000007429 general method Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 241000222519 Agaricus bisporus Species 0.000 description 6
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 6
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 6
- 229920001954 Restylane Polymers 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000006227 byproduct Substances 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 239000006196 drop Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 229950006780 n-acetylglucosamine Drugs 0.000 description 6
- 239000002105 nanoparticle Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 5
- 206010024769 Local reaction Diseases 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 239000002956 ash Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000001879 gelation Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 238000011179 visual inspection Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 4
- 238000002050 diffraction method Methods 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229960002442 glucosamine Drugs 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000000399 optical microscopy Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 229940010747 sodium hyaluronate Drugs 0.000 description 4
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010011026 Corneal lesion Diseases 0.000 description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010024604 Lipoatrophy Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 238000000237 capillary viscometry Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 238000002316 cosmetic surgery Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 238000002270 exclusion chromatography Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 230000001050 lubricating effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000003746 surface roughness Effects 0.000 description 3
- UWFRVQVNYNPBEF-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(C)C=C1C UWFRVQVNYNPBEF-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000003899 Foreign-Body Granuloma Diseases 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 240000000599 Lentinula edodes Species 0.000 description 2
- 235000001715 Lentinula edodes Nutrition 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Chemical group CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000031737 Tissue Adhesions Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940106681 chloroacetic acid Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007489 histopathology method Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000005499 meniscus Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000000569 multi-angle light scattering Methods 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 238000003918 potentiometric titration Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010070245 Foreign body Diseases 0.000 description 1
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100028965 Proteoglycan 4 Human genes 0.000 description 1
- 208000014139 Retinal vascular disease Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- TZIZWYVVGLXXFV-FLRHRWPCSA-N Triamcinolone hexacetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@@H]2O TZIZWYVVGLXXFV-FLRHRWPCSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000003728 Vulvodynia Diseases 0.000 description 1
- 206010069055 Vulvovaginal pain Diseases 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910001617 alkaline earth metal chloride Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 108010009030 lubricin Proteins 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000001074 muscle attachment cell Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 239000002102 nanobead Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 230000004820 osteoconduction Effects 0.000 description 1
- 230000004819 osteoinduction Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960004221 triamcinolone hexacetonide Drugs 0.000 description 1
- 238000000196 viscometry Methods 0.000 description 1
- 239000003932 viscosupplement Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/12—Powdering or granulating
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2405/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
- C08J2405/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Definitions
- TITLE Chitosan-based beads, preparation, compositions and applications
- the present invention relates to beads which can be administered and in particular which can be injected, implanted or instilled, in a human or animal being, comprising or consisting of a hydrogel matrix comprising at least one cross-linked carboxyalkyl chitosan.
- the present invention relates to compositions which can be administered and in particular which can be injected, implanted or instilled, in a human or animal being, comprising beads comprising or consisting of a hydrogel matrix comprising at least one cross-linked carboxyalkyl chitosan.
- the present invention also relates to a method for preparing these beads, compositions, in particular in the form of a suspension or dispersion, comprising them, as well as their applications, in particular their applications by administration to a human or animal, in particular by injection through of an injection needle or an endoscopic system, by implantation, by instillation or by any other route suitable for the intended indication.
- the present invention relates in particular to beads which can be administered to a human being or an animal comprising or consisting of a hydrogel matrix comprising at least one carboxyalkyl chitosan crosslinked by covalent bonds, compositions comprising them, their method of manufacture and their various applications, in particular in the therapeutic, rheumatological, orthopedic, ophthalmological, aesthetic medicine, plastic surgery, internal, dermatological, gynecological or cosmetic fields.
- bioresorbable beads which are not in hydrogel form, but they present risks of inducing foreign body reactions and granulomas. They are therefore limited to localized use at deep tissue layers, and for example, they cannot be administered in the dermis. Of such microspheres can be injected intraocularly (Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles, Nature Comm 11, 694, 2020).
- the beads according to the invention must be suitable for use in humans or animals, in particular in terms of cohesion, harmlessness, immunocompatibility, bioresorbability, biomechanical properties, ease of administration and life or activity.
- the compositions of the state of the art do not all satisfactorily exhibit such properties and would therefore not be in accordance with the present invention.
- HA cross-linked hyaluronic acid
- the shape obtained by extrusion is aspherical and irregular, which leads to a risk of foreign body reaction and granuloma in general higher than with a spherical shape, as described among others by Lemperle (Biocompatibility of injectable microspheres, Biomed J Sci Tech Res 2, 1, 2018).
- hydrogel beads obtained by extrusion require greater force for injection through a fine needle than spherical hydrogel beads. It is therefore recommended to use spherical hydrogel beads to promote good short- and long-term tolerance and ease of injection through fine needles.
- Luo et al. do not describe any of the following properties: mechanical resistance, elasticity, volumization, immunocompatibility, injectability via a needle, ability to eliminate residues (salt and crosslinking agent) by the washing step without damaging the beads.
- the present inventors have discovered that the method of Luo et al. not suitable for the preparation of hydrogel beads starting from highly substituted and/or acetylated chitosan derivatives and with the crosslinking agent BDDE (preferred to glutaraldehyde).
- the chitosan derivative used by Luo et al. exhibits a degree of acetylation and a degree of substitution that do not provide acceptable immunoreactivity. It is therefore not possible for a person skilled in the art to draw a satisfactory lesson from this document in order to develop the beads according to the present invention.
- the present invention aims to solve the technical problem of providing injectable beads with good tolerance for the intended indications after administration in humans or animals, in particular by injection or implantation, in particular in the therapeutic fields, surgical and aesthetic.
- the aim of the present invention is to solve the technical problem consisting in providing such injectable beads for volumization indications (for example, volumizing effect/remodeling of the contours of the face/body in aesthetic medicine or to treat lipoatrophies) or for delivery of drugs.
- volumization indications for example, volumizing effect/remodeling of the contours of the face/body in aesthetic medicine or to treat lipoatrophies
- the aim of the invention is in particular to solve the technical problem consisting in providing bioresorbable beads, suitable for use in contact with a tissue of a human or animal being, acceptable in terms of biomechanical properties, lifespan or in situ activity, seeking good health safety, including an acceptable short- and long-term immunological reaction and/or foreign body reaction, and presenting beneficial effects, in particular in the context of regenerative medicine or anti-aging medicine, for example in the therapeutic, rheumatological, orthopedic, gynecological, ophthalmological, aesthetic medicine, plastic surgery, internal surgery, dermatological or cosmetic fields.
- the aim of the present invention is to solve the technical problem of providing such injectable beads having satisfactory stability during their storage and suitable for the intended indication.
- the object of the present invention is in particular to solve the technical problem consisting in providing such injectable beads having satisfactory tolerance, physicochemical properties, and a volumizing effect and for a sufficient duration after subcutaneous implantation.
- the aim of the invention is to solve the technical problem of providing balls with properties that can be modulated according to the intended indication.
- the object of the invention is to solve the technical problem consisting in providing beads which withstand purification steps by washing in an aqueous medium in order to eliminate the undesirable residues of the process and to balance the pH and the osmolality of the beads with those of a physiological environment.
- the present invention also aims to solve the technical problem of providing bioresorbable injectable beads with a prolonged effect over time, in particular in terms of volumizing effect and / or delivery of at least one compound of interest. for the intended indication (therapeutic active ingredient, nutrient, etc.)
- the present invention also aims to solve the technical problem of providing (injectable) beads having an essentially spherical shape and a smooth, non-rough surface.
- the object of the present invention is in particular to solve the technical problem consisting in providing such beads having satisfactory ease of injection when they are intended for administration by injection, without affecting the integrity of the beads at the outlet of the injection system. 'injection.
- Another object of the present invention is to solve the technical problem consisting in providing beads which can be suspended in an aqueous phase and which remain intact during their storage in such a suspension.
- the present invention also aims to solve the technical problem of providing beads that can be suspended in an aqueous phase and remain intact during their sterilization in such a suspension, in particular by a moist heat sterilization process.
- the object of the present invention is to solve the technical problems stated above by providing beads of chitosan derivatives.
- beads for injection into the human or animal body, they must be biocompatible with the tissue(s) in which they are injected or implanted.
- they comprise a polymer matrix, preferably biopolymer, which is non-toxic and non-immunoreactive.
- the polymers of the matrix of the beads according to the invention are advantageously bioresorbable and are neither toxic nor immunoreactive.
- Preference is given to the carboxyalkyl chitosan derivatives described in applications PCT/EP2018/080763 and PCT/EP2018/080767 from KIOMED PHARMA, which clearly show that the matrices are neither toxic nor immunoreactive.
- any chitosan derivative cannot be used to form hydrogels acceptable for use in humans or animals, particularly in terms of immunocompatibility (or immunoreactivity).
- immunocompatibility is meant any substance foreign to the human body or other living organisms which cannot stimulate cells or the immune system resulting in a specific immune response with antigen.
- Application PCT/EP2020/064159 relates to the use of hydrogel matrices prepared by crosslinking such chitosan derivatives. It was considered for a time to use a matrix of such a cross-linked chitosan derivative according to this international application PCT/EP2020/064159 to prepare beads meeting the objectives of the present invention.
- the inventors have built a research program.
- they envisaged preparing the spherical hydrogel beads based on carboxyalkyl chitosan according to PCT/EP2018/080763 and PCT/EP2018/080767, by following the various methods described in the literature for the carboxyalkyl derivatives of chitosan.
- the invention relates in particular to a composition
- a composition comprising an aqueous phase comprising a plurality of beads, the beads comprising or consisting of a hydrogel matrix comprising at least one carboxyalkyl chitosan having glucosamine units, N-acetyl-glucosamine units and glucosamine substituted by a carboxyalkyl group, the carboxyalkyl chitosan being crosslinked by covalent bonds between the chains of carboxyalkyl chitosan and/or co-crosslinked by covalent bonds with one or more other polymers.
- the invention also relates to one or more beads for injection into a human or animal, the beads comprising or consisting of a hydrogel matrix comprising at least one carboxyalkyl chitosan having glucosamine units, N-acetyl-glucosamine units and glucosamine units substituted by a carboxyalkyl group, said carboxyalkyl chitosan exhibiting a degree of acetylation greater than 30% and up to 80%, expressed as number of moles of N-acetyl groups relative to the number of moles of total glucosamine units, said carboxyalkyl chitosan being crosslinked by covalent bonds between the chains of carboxyalkyl chitosan and/or co-crosslinked by covalent bonds with one or more other polymers.
- Carboxyalkyl chitosan Carboxyalkyl chitosan
- chitosan derivatives are known such as carboxyalkyl chitosan described in the Kiomed Pharma patent applications filed under the numbers PCT / EP2018 / 080763 and PCT / EP2018 / 080767 and their family whose contents are integrated into the present invention by reference .
- the international application from Kiomed Pharma, PCT/EP2020/064159 describes crosslinked carboxyalkyl chitosans, alone or co-crosslinked with another polymer, such as for example a hyaluronan.
- a matrix according to the present invention can be characterized by the starting carboxyalkyl chitosan, which is crosslinked and/or co-crosslinked with one or more other polymers to form a matrix according to the invention.
- a carboxyalkyl chitosan (of fungal origin) having glucosamine units, N-acetyl-glucosamine units and glucosamine units substituted by a carboxyalkyl group is used, said carboxyalkyl chitosan preferably having a degree of substitution by a carboxyalkyl group greater than 20%, expressed as the number of moles of the substituent relative to the number of moles of total units.
- chitosan derivative Also referred to as chitosan derivative or substituted chitosan.
- Carboxyalkyl chitosan is prepared by substitution of chitosan.
- a carboxyalkyl chitosan is prepared according to the Kiomed Pharma patent applications filed under the numbers PCT/EP2018/080763 and its family (in particular FR 17 61314 and EP 18799772.1) and PCT/EP2018/080767 and its family (in particular FR 17 61323 and EP 18799773.9), and PCT/EP2020/064159 and its family (in particular FR 19 05504) which are incorporated here by reference in particular to illustrate the preparation of a carboxyalkyl chitosan.
- Chitosan is for example referenced under CAS number 9012-76-4.
- the chitosan used for the invention is advantageously of fungal origin, and preferably derived from the mycelium of a fungus of the Ascomycete type, and in particular from Aspergillus niger, and/or from a Basidiomycete fungus, and in particular Lentinula edodes (shiitake) and/or Agaricus bisporus (button mushroom).
- the chitosan is derived from Agaricus bisporus.
- the chitosan is preferably very pure, that is to say containing few impurities resulting from its fungal origin or from the manufacturing process, and of a microbiological quality compatible with its use as an implant or pharmaceutical composition.
- a method of preparing chitosan is that described in patents WO 03/068824 (EP 1483299; US 7,556,946).
- the chitin is placed in aqueous suspension in the presence of sodium hydroxide, then the medium is brought to high temperature for a variable period depending on the desired molecular weight.
- the chitosan is then purified by solubilization in an acid medium and precipitated in an alkaline medium, washed and dried.
- the chitosan is of sufficiently pure grade for pharmaceutical use.
- the chitosan is advantageously purified and then preferably dried.
- the method of the invention may comprise a step of drying the carboxyalkyl chitosan, then optionally of grinding the latter to obtain a powder.
- the chitosan can be dried, for example, by evaporation of the water, for example by a spray-drying (atomization) or fluidized-bed process, or by heat-drying under vacuum or at atmospheric pressure, or else by freeze-drying.
- This chitosan can then be substituted to produce a carboxyalkyl chitosan as for example described in the invention.
- Such a carboxyalkyl chitosan is then used to prepare the beads according to the invention.
- the DA and DS are expressed as a function of the carboxyalkyl chitosan before formation of the beads.
- the degree of acetylation (DA) of chitosan is determined as for example described in patent applications WO 2017009335 and WO 2017009346 by potentiometric titration.
- the DA of chitosan and of carboxyalkylated chitosan can be measured by known methods for chitosan, such as proton NMR in the liquid phase, carbon-13 NMR in the solid phase, infrared spectrometry, UV-visible spectrometry.
- the carboxyalkyl chitosan has a degree of acetylation of less than 30%, for example ranging from 5% to 30%, expressed in number of moles of N-acetyl-glucosamine units relative to the number of moles of total units.
- the carboxyalkyl chitosan has a degree of acetylation of between 30 and 80%, expressed in number of moles of N-acetyl-glucosamine units relative to the number of moles of total units.
- the degree of acetylation is expressed as the number of N-acetyl groups (of D-glucosamine units) relative to the number of total glucosamine units present in chitosan (N-acetyl-D-glucosamine, N-acetyl-D-glucosamine substituted, D-glucosamine and substituted D-glucosamine).
- the carboxyalkyl chitosan has a degree of acetylation of between 30 and 75%, expressed as the number of N-acetyl groups relative to the number of total glucosamine units. According to a variant, the degree of acetylation ranges from 35 to 50%.
- the degree of acetylation ranges from 40 to 60%.
- the degree of acetylation ranges from 50 to 75%.
- the degree of acetylation of carboxalkyl chitosan can be determined by carbon-13 NMR in the solid phase or by proton NMR in the liquid phase.
- the carboxyalkyl chitosan advantageously exhibits a controlled degree of acetylation.
- chitosan having a controlled degree of acetylation is meant a product whose degree of acetylation, that is to say the proportion of N-acetyl-glucosamine units, can be adjusted in a controlled manner, in particular by an acetylation reaction.
- the carboxyalkyl chitosan is reacetylated.
- the process for preparing the carboxyalkyl chitosan according to the invention comprises the preparation of a chitosan of fungal origin, the reacetylation of the chitosan and the carboxyalkylation of the reacetylated chitosan.
- the invention relates to a reacetylated carboxyalkyl chitosan.
- the invention relates to an anionic carboxyalkyl chitosan.
- chitosan in an aqueous medium, preferably slightly acidified (pH 6 for example).
- Acetic anhydride can be added to the chitosan solution all at once or several times.
- a basic agent is then added, such as sodium hydroxide and/or urea, for example.
- An alkylating agent is then added, such as sodium monochloroacetate (i.e. the sodium salt of chloroacetic acid) or chloroacetic acid. Then the substituted chitosan is purified, recovered and dried.
- the process for preparing the carboxyalkyl chitosan according to the invention comprises the preparation of a chitosan, the carboxyalkylation of the chitosan, then the reacetylation of the carboxyalkylated chitosan.
- a method allows precise control of the degree of acetylation of the final carboxyalkyl chitosan, and in particular to obtain a high degree of acetylation, for example above 40%.
- the invention relates to a reacetylated then carboxyalkylated chitosan or a reacetylated carboxyalkyl chitosan.
- the process for preparing the carboxyalkyl chitosan according to the invention comprises the preparation of a chitin of fungal origin, the carboxyalkylation of the chitin, and optionally the reacetylation of the carboxyalkylated chitin to obtain the carboxyalkyl chitosan according to the invention. .
- the method for preparing the carboxyalkylated chitosan according to the invention comprises the preparation of a chitin of fungal origin, a deacetylation of the chitin, the carboxyalkylation of the chitin, and optionally the reacetylation of the carboxyalkylated chitin to obtain the carboxyalkyl chitosan according to the invention.
- the carboxyalkyl chitosan has an average molecular mass of less than 500,000.
- the substituted chitosan preferably has an average molecular weight of 50,000 to 400,000.
- the average molecular mass is the molecular mass of the carboxyalkyl chitosan before formation of the beads and crosslinking.
- the average molecular weight is the viscosity average molecular weight (Mv), calculated from the inherent viscosity. This expression is customary for those skilled in the art.
- the inherent viscosity (q) is measured by capillary viscometry, with a capillary viscometer of the Ubbelohde type, according to the method of monograph 2.2.9 of the European Pharmacopoeia.
- the solution flow time is measured through a suitable capillary tube (Lauda, for example the Ubbelohde 510 01 capillary tube with a diameter of 0.53 mm) using an I-Visc automatic viscometer (Lauda).
- a suitable capillary tube Li-Visc automatic viscometer
- I-Visc automatic viscometer Li-Visc automatic viscometer
- the constants K and a have a value of 0.0686 and 0.7638, respectively, as previously determined for chitosan (unsubstituted) by steric exclusion chromatography with a MALLS detector.
- the intrinsic viscosity of the carboxylakyl chitosan can usually be expressed to qualify its average molecular mass.
- the glucosamine units are D-glucosamine units (D-glucosamine units, N-acetyl-D-glucosamine units, and at least one of D-glucosamine units and N-acetyl- D-glucosamine being substituted).
- a substituted chitosan has substitution of D-glucosamine units only.
- a substituted chitosan has substitution of D-glucosamine and N-acetyl-D-glucosamine units simultaneously, and wherein the carboxyalkyl group is covalently bonded, alternatively to the amine groups of chitosan only, or another variant to the amine and hydroxyl groups of chitosan simultaneously.
- the substitution is usually only partial, not all units are necessarily substituted.
- the degree of substitution of the D-glucosamine units expressed as the number of moles of D-glucosamine units relative to the number of moles of total units (D-glucosamine and N-acetyl-D-glucosamine units, substituted or not) of the substituted chitosan, ranges from 30% to 250%.
- said carboxyalkyl chitosan has a degree of substitution by a carboxyalkyl group greater than 20%, for example greater than 50%, for example less than 200%, expressed in number of moles of the substituent relative to the number of moles of total units.
- the degree of substitution by a carboxyalkyl group greater than 50% expressed as the number of moles of the substituent relative to the number of moles of total units.
- the degree of substitution of the D-glucosamine units expressed as the number of moles of D-glucosamine units relative to the number of moles of total units (D-glucosamine and N-acetyl-D-glucosamine units, substituted or not) of the substituted chitosan, ranges from 50% to 200%, and even more preferably greater than 70%.
- the degree of substitution by a carboxyalkyl group of less than 80% expressed as the number of moles of the substituent relative to the number of moles of total units.
- substitution takes place by covalent bond.
- the carboxyalkyl chitosan is an N,O-carboxyalkyl chitosan.
- the proportion of units substituted by a carboxyalkyl group in the O position (03 and/or 06 of the glucosamine and/or N-acetyl-glucosamine units) and/or in the N position (of the glucosamine units) varies.
- the degree of substitution can therefore be greater than 100%.
- the degree of substitution (DS) and the degree of acetylation (DA) of the carboxyalkyl chitosan are measured by magnetic resonance spectrometry (NMR) of carbon 13 in solid phase, using a Bruker Spectrometer (Avance III HD 400MHz, equipped with a PH MAS VTN 400SB BL4 NP/H probe).
- NMR magnetic resonance spectrometry
- the spectrum is recorded at room temperature, a relaxation time between 1 and 8 seconds, a number of scans between 64 and 512.
- the areas of the carbon signals are determined after deconvolution.
- the DA of the carboxyalkyl chitosan is calculated according to Formula 1, and the DS according to Formula 2, where I represents the area of the signal of the carbon considered.
- the ranges of the degrees of substitution are expressed in relation to the result of the analysis by solid-phase carbon-13 NMR in the present description, given its ease of implementation.
- the degree of carboxyalkylation of chitosan can advantageously vary from 20 to 250%, preferably from 50 to 200%, and for example from 70 to 170%, expressed in number of moles of carboxyalkyl relative to the number of moles of total units.
- the degree of carboxyalkylation (DS) of the chitosan can advantageously vary from 40 to 130%, and for example from 70 to 130%, expressed in number of moles of carboxyalkyl relative to the number of moles of total units.
- the degree of substitution of chitosan is typically correlated to the amount of reactants relative to chitosan at the start of the reaction.
- carboxyalkylating agents mention may be made of acid chlorides (or their salts, for example sodium monochloroacetate), such as for example those bearing one or more carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, etc. groups.
- the present invention relates to a carboxyalkyl chitosan where the alkyl part of the carboxyalkyl is C1-C5, linear or branched.
- the present invention relates to a carboxymethyl chitosan.
- the substituted chitosan is an N-carboxyalkylated chitosan.
- the substituted chitosan is an O-carboxyalkylated chitosan.
- the substituted chitosan is an N-carboxyalkylated and O-carboxyalkylated chitosan.
- the present invention relates, according to a second aspect, to a chitosan derivative having glucosamine units, N-acetyl-glucosamine units and glucosamine units substituted by a carboxyalkyl group, said carboxyalkyl chitosan having a zeta potential, measured at pH 7.5, lower or equal to -10 mV, and preferably less than or equal to -15 mV.
- a chitosan derivative makes it possible to limit the immune response of a subject to whom the chitosan derivative or a composition comprising it has been administered, typically by instillation, injection or implantation.
- the zeta potential, measured at pH 7.5 is less than or equal to -18 mV.
- the carboxyalkyl chitosan has a zeta potential, measured at pH 7.5, less than or equal to -22 mV, and preferably less than or equal to -24 mV.
- the substituted chitosan has a degree of substitution (DS) ranging from 20 to 80%, and preferably from 40 to 60%, and a degree of acetylation (DA) from 30 to 80%, and preferably from 30 to 75%.
- DS degree of substitution
- DA degree of acetylation
- the substituted chitosan has a degree of substitution ranging from 50 to 200%, and preferably from 70 to 200%, and a degree of acetylation from 30 to 80%, and preferably from 30 to 75%.
- the substituted chitosan has a degree of substitution ranging from 90 to 200%, and preferably from 90 to 150%, and a degree of acetylation from 30 to 80%. According to a specific variant, the substituted chitosan has a degree of substitution ranging from 90 to 200%, and preferably from 90 to 150%, and a degree of acetylation from 30 to 60.
- the substituted chitosan has a degree of substitution ranging from 90 to 200%, and preferably from 90 to 150%, and a degree of acetylation from 40 to 75%.
- chitosan By substituting chitosan, it was possible to prepare a solution of a soluble carboxyalkyl chitosan in an aqueous solution whose pH varies over a wide range, whereas unsubstituted chitosan is only soluble at pH below pH about 6.
- the carboxyalkyl chitosan thus has an ability to be solubilized at different pH thanks to the presence of carboxyalkyl groups which modify its solubility profile, and in particular at physiological pH or at other pH when physiological fluids are modified by a pathology, for example an inflammatory pathology.
- soluble in water it is meant that the carboxyalkyl chitosan does not present any cloudiness visible to the naked eye when it is placed in aqueous solution. More specifically, one can confirm the solubility, that is to say the absence of cloudiness, of a solution of carboxyalkyl chitosan at a concentration for example of 1% (m/m) in water or a buffer, for example a phosphate buffer, by an optical density of less than 0.5, and preferably less than 0.2, measured by UV-visible spectrometry at a wavelength of 500 nm with reference to a reference tank comprising only the aqueous solvent used for the measured sample, but in the absence of the substituted chitosan.
- carboxyalkyl chitosan is sterile.
- crosslinked by covalent bonds between the carboxyalkyl chitosan chains means that the main chain of chitosan (also called the backbone of chitosan or in English "chitosan backbone”) is covalently linked to one or more main chains of chitosan .
- a three-dimensional network of chitosan molecules is thus advantageously obtained.
- the invention is not limited to a particular covalent crosslinking method, but a method using a chemical molecule serving as crosslinking agent, also called crosslinking agent, is preferred.
- the concept of "crosslinked by covalent bonds between the carboxyalkyl chitosan chains” is understood in particular by covalent bonds involving crosslinking agents linking molecules of carboxyalkyl chitosan. They are therefore covalent bonds between carboxyalkyl chitosan chains via chains of atoms (typically, the part of the crosslinking agent which is located between its reactive functions).
- the carboxyalkyl chitosan is crosslinked.
- the beads according to the invention comprise or consist of a hydrated matrix and in the form of a hydrogel.
- hydrogel is meant the conventional meaning of this term, and in particular namely a three-dimensional (3D) network of at least one hydrophilic polymer which can swell in water and retain a significant quantity of water while retaining its structure. due to the cross-linking of the individual chains of the polymer(s).
- hydrogel ball is meant a hydrated ball that contains at least 70% water by mass relative to its total wet mass. Typically, a hydrogel bead is able to retain this mass of water under ambient conditions or after administration into tissue.
- the matrix comprises at least one polymer, for example at least one hyaluronan, optionally crosslinked on itself by covalent bonds and/or co-crosslinked by covalent bonds with the carboxyalkyl chitosan.
- Crosslinked on itself or “on themselves” means that the molecules can comprise covalent crosslinking bonds intra and/or inter-molecular chains.
- the matrix according to the hydrogel invention comprises or consists of one or more bioresorbable polymers including at least one carboxyalkyl chitosan.
- the matrix according to the invention forming a hydrogel consists of a carboxyalkyl chitosan.
- the matrix according to the invention forming a hydrogel comprises or consists of a carboxyalkyl chitosan crosslinked on itself and/or co-crosslinked with another polymer, and of one or more other biopolymers, optionally crosslinked or coreticulated with carboxyalkyl chitosan.
- the invention therefore comprises several variants, including in particular:
- hydrogel matrix comprises or consists of a carboxyalkyl chitosan cross-linked to itself and no other polymer in the hydrogel matrix.
- hydrogel matrix comprises or consists of a carboxyalkyl chitosan crosslinked on itself and one or more other polymers, crosslinked or not on themselves, in the hydrogel matrix.
- hydrogel matrix comprises or consists of a carboxyalkyl chitosan co-crosslinked with one or more other polymers, and in which the carboxyalkyl chitosan and/or the other polymer(s) are optionally crosslinked to them themselves.
- said carboxyalkyl chitosan is co-crosslinked with another polymer.
- the bioresorbable polymers according to the invention are biopolymers of natural origin, and for example existing naturally in a human or animal tissue, for example they are polysaccharides, proteins, and any other polymer present at the tissue level. , cellular.
- the biopolymer other than carboxyalkyl chitosan is chosen from polysaccharides or proteins, and preferably chosen from the following biopolymers or any of their combinations: elastin, hyaluronan, chondroitin, fibrin, collagen, dextran, cellulose, carboxyalkyl cellulose, lubricin, mucin, silk, albumin, and any of their derivatives.
- a biopolymer can be native or have a modified native structure.
- the other biopolymer is chosen from a polysaccharide, oxidized or not, crosslinked by covalent bonds or not, for example a glycosaminoglycan, and in particular a hyaluronan, such as for example hyaluronic acid, sodium hyaluronate or any of their salts or derivatives.
- the bioresorbable polymers are synthetic polymers.
- the matrix according to the invention constituting the hydrogel beads comprises or consists of a carboxyalkyl chitosan and a hyaluronan, the carboxyalkyl chitosan being crosslinked on itself and/or co-crosslinked with the hyaluronan.
- these two polymers are advantageously crosslinked on themselves and/or co-crosslinked with each other.
- the hyaluronan used for the preparation of the beads has an average molecular mass of less than 5,000,000 as determined by capillary viscometry or steric exclusion chromatography.
- the molecular mass of hyaluronan is sometimes expressed via its intrinsic viscosity measured by viscometry capillary, well correlated with molecular mass via the Mark Houwink relationship.
- the hyaluronan used for the preparation of the beads may have a so-called “high” intrinsic viscosity according to one variant (from approximately 3 to 4.25 m 3 /kg), “medium” (from 1.5 to 3 m 3 /kg ) according to another variant, or even “low” (from 0.1 to 1.5 m 3 /kg) according to another variant, depending on the properties desired for the beads.
- the hyaluronan is obtained by fermentation, for example with Streptococcus equii. According to another variant, it is produced by extraction from rooster combs.
- the matrix comprises at least one hyaluronan crosslinked by covalent bonds.
- cross-linked hyaluronan comprises covalent bonds between different hyaluronan chains.
- hyaluronan can be cross-linked with each other, such as hyaluronans with different molecular masses or different hyaluronan salts.
- the invention thus relates to a hydrogel in the form of beads comprising or consisting of a matrix comprising at least one hyaluronan co-crosslinked by covalent bonds with carboxyalkyl chitosan.
- the balls according to the invention have a water content greater than 80%, preferably greater than or equal to 85%, for example greater than or equal to 90%, by mass relative to the total mass of the ball.
- the beads according to the invention are not toxic to humans or animals; that is to say without a toxic component or degrading into a toxic component, as verified according to the standards in force for the product and the indication which are targeted, depending on whether it is a medical device, a drug or a product veterinary, for example using an in vitro cytotoxicity model and/or an animal model, for example to verify the absence of chronic toxicity after oral or systemic administration.
- the beads are biocompatible and do not present any problem of local tolerance, nor of unacceptable immunoreactivity for the intended indication, for the tissue in or on which they are administered.
- the balls according to the invention do not include any component of animal origin.
- the beads according to the invention do not comprise alginate, gelatin, carrageenan, or native chitosan, that is to say which is not a derivative of chitosan.
- the beads according to the invention comprise at least one carboxyalkyl chitosan and optionally one hyaluronan.
- the name hyaluronan includes hyaluronic acid and its salts.
- the beads according to the invention are bioresorbable, preferably with a long residence time or adaptable to the intended indication.
- bioresorbable means a polymer which is gradually degraded/absorbed by natural biological/physiological phenomena, and typically over several days, preferably over several weeks or months (maximum duration depending on the intended indication), into components of low molecular mass, eliminable by natural processes when injected subcutaneously or intradermally, into the body of a warm-blooded animal, or a human being.
- the balls according to the invention can be sterilized, preferably by moist heat sterilization.
- the balls according to the invention essentially retain their characteristics and properties after sterilization, in particular by moist heat or by filtration.
- the beads are preferably sterilized once in suspension in a final phase.
- the beads according to the invention are injectable through a needle suitable for the indication, that is to say that the force applied to inject them must be acceptable, that the act of injection must not cause jerks, and that it must not cause any alteration of the ejected balls.
- the injection force guarantees a simple, precise and well-controlled medical act.
- the injection must happen regularly, smoothly; an “easy” injection of the beads or compositions according to the invention is thus preferred.
- Easy injection it is preferably meant that the force to be exerted on a syringe is less than 50 Newton, preferably less than 40 Newton, to cause a composition according to the invention to flow through a needle defined for the injection.
- beads that can be injected through a needle are preferred in a diameter range from 25G to 34G.
- beads easily injected through a needle in a range of 27G to 34G are preferred.
- beads easily injected through a needle in the range of 18G to 25G are preferred.
- the beads according to the invention have the desired characteristics after injection, implantation or instillation via the administration device used.
- the hydrogel beads according to the invention have an average diameter by volume of 20 ⁇ m to 450 ⁇ m in their hydrated form.
- the average diameter of the balls is measured according to a particle size analysis method, for example by laser diffractometry (volume average diameter), or even by analysis of images recorded by a microscopy technique (number average diameter), for example optical , electronic scanning, atomic force or confocal scanning.
- number average diameter for example optical , electronic scanning, atomic force or confocal scanning.
- the diameter of the beads in their dehydrated form can also be measured by these techniques.
- the beads according to the invention have an average diameter by volume of 25 ⁇ m to 250 ⁇ m in their hydrated form, in particular to minimize the response to foreign bodies and prevent the beads from migrating into the tissues.
- the beads according to the invention have an average diameter by volume of between 1 ⁇ m and 20 ⁇ m in their hydrated form.
- the beads according to the invention have a volume-average diameter of less than 1000 nm, and preferably less than 500 nm.
- a volume-average diameter of less than 1000 nm, and preferably less than 500 nm.
- the size distribution of beads depends on the intended application.
- the balls are spherical to minimize foreign body reactions after injection or implantation and in a manner adapted to the intended indication.
- the beads according to the invention have a slightly rough, and preferably smooth, surface morphology in their hydrated form.
- a smooth or slightly rough surface minimizes the foreign body reaction.
- the balls according to the invention have a negative or neutral surface charge, in particular by measuring the zeta potential.
- a negative or neutral surface charge minimizes the foreign body reaction.
- Beads of a homogeneous hydrogel that is to say non-fragmented and without solid component in the core or on the surface of the beads, are preferred for many applications.
- the balls are transparent.
- beads of a hydrogel which remain substantially intact and homogeneous when they are incorporated into their final phase (medium), for example an aqueous phase, and their final packaging, for example a syringe, as well as throughout their storage period.
- their final phase for example an aqueous phase
- their final packaging for example a syringe
- the balls according to the invention are flexible in their hydrated form, that is to say that their shape can be modified when they are subjected to a certain deformation force (for example compression or shearing), without breaking and are able to return to their original shape once the ball is released from the deforming force.
- a certain deformation force for example compression or shearing
- the balls according to the invention have good resistance to the mechanical stresses imposed by the implantation site.
- the beads according to the invention thus have a good ability to augment, fill and/or remodel a tissue in which they are injected or implanted.
- the beads according to the invention are suitable for use in humans or animals, in particular in terms of safety, immunocompatibility, bioresorbability, biomechanical properties and lifespan or activity.
- the compositions of the state of the art do not all satisfactorily exhibit such properties and would therefore not be in accordance with the present invention.
- the present invention also relates to a process for preparing the beads according to the invention.
- the present invention relates in particular to a method for preparing a plurality of beads as defined according to the invention, said method comprising: the preparation of an aqueous solution of a carboxyalkyl chitosan, in the presence or not of at least one another polymer, with at least one crosslinking agent, preferably carried out at alkaline pH; forming droplets of this solution in the form of a plurality of beads; the crosslinking by the crosslinking agent of the carboxyalkyl chitosan, and optionally of at least the other polymer if present; and obtaining a plurality of balls as defined according to the invention.
- the process according to the invention comprises the formation of droplets based on the bioresorbable polymer(s) then their stabilization by covalent crosslinking of the polymer(s).
- a method according to the invention comprises dissolving a carboxyalkyl chitosan and optionally other polymers and forming droplets of this solution, then the covalent crosslinking in the form of hydrogel beads, possibly their classification to select the desired bead dimensions.
- the beads are incorporated into an aqueous phase, optionally comprising one or more other polymers.
- one or more active agents are added to the aqueous solution comprising the carboxyalkyl chitosan, and optionally one or more other polymers, before the formation of the droplets. It is thus possible to prepare a solution or a suspension comprising at least one active agent depending on whether the active agent is soluble or insoluble in this aqueous solution, respectively, then to form the beads according to the invention, so as to encapsulate one or more active agents in the balls.
- a carboxyalkyl chitosan and optionally one or more other polymers, are dissolved in an aqueous solution containing the crosslinking agent, preferably at alkaline pH.
- the aqueous solution also comprises one or more crosslinking agents.
- the alkaline agent typically sodium hydroxide, for example at a mass concentration of between 0.1 and 5%.
- the carboxyalkyl chitosan with other water-soluble polymers, for example a biopolymer, for example a polysaccharide, for example hyaluronan.
- a biopolymer for example a polysaccharide, for example hyaluronan.
- the droplets are placed in the presence of an aqueous phase optionally comprising an organic solvent, for example an alcohol, for example ethanol.
- an organic solvent for example an alcohol, for example ethanol.
- the method comprises the coagulation of the droplets, in the presence of at least one coagulation agent, in the form of a plurality of beads before their crosslinking.
- the method comprises the formation of droplets of carboxyalkyl chitosan and optionally one or more other polymers if present, optionally followed by the coagulation of the droplets, for example by ionic gelation (non-covalent bonds).
- the polymer droplets can be formed by emulsification in a hydrolipidic medium, oil in water or water in oil. Droplets can be formed by passing the solution through any tube with a diameter adapted to the desired bead diameter, at an adequate flow rate.
- atomizer also called nebulizer
- a binary nozzle with a diameter of 2.8 mm (Büchi) is used.
- the droplet formation system is adapted, for example the internal diameter of the nozzle.
- the droplet formation system or its parameters are adapted according to the viscosity of the polymer solution.
- coagulation of the droplets is carried out in a solution called “coagulation bath” comprising a coagulation agent.
- the agent is an alkaline-earth metal chloride, typically calcium chloride, which induces gelation by ionic interactions with the carboxyalkyl chitosan.
- the coagulation bath is an aqueous solution in the presence of a solvent of the alcohol type, for example ethanol.
- the coagulation bath consists of a water/solvent volume ratio of 90/10 to 10/90, typically 30/70, 20/80 or 80/20.
- the concentration of calcium chloride in the coagulation bath is 10 to 200 mg/mL.
- the coagulation is carried out at room temperature, that is to say without heating, preferably at a temperature of 20 to 25°C.
- the coagulated beads includes a step of classifying the coagulated beads to control their distribution.
- the plurality of beads obtained after crosslinking is subjected to steps of purification by washing and balancing of the pH and osmolality in a physiologically acceptable medium.
- the process comprises the crosslinking of the polymer(s) put in the form of droplets, optionally coagulated, preferably via a crosslinking agent present in the polymer solution from the first stage.
- the crosslinks are formed by a crosslinking agent forming said covalent bonds.
- chitosan chains can be crosslinked, for example by reaction with one or more crosslinking agents, for example chosen from the crosslinking agents used for the crosslinking of biopolymers, in particular polysaccharides, such as for example 1,4 butanediol diglycidyl ether, 1 -bromo-3,4- epoxybutane, 1 -bromo-4,5-epoxypentane, l-chloro-2,3-epithio- propane, 1 -bromo-2,3-epithiopropane, l-bromo-3, 4-epithio-butane, 1-bromo-4,5-epithiopentane, 2,3-dibromopropanol, 2,4-dibromobutanol, 2,5-dibromopentanol, 2,3-dibromopropanethiol,2,4-dibromobutanethiol, and 2 d
- Genipin is a cross-linking agent of natural origin used to cross-link polysaccharides, in particular carboxymethyl chitosan (Yang et al. Ophthalmic drug-loaded N,0-carboxymethyl chitosan hydrogels, Acta Pharmacol Sin 31, 1625, 2010). Genipin stains the hydrogel a dark blue to black color, which may be an advantage in some indications.
- the crosslinking agent is an agent of polyepoxide type, for example difunctional.
- 1,4-butanediol diglycidyl ether (BDDE) or ethylene glycol diglycidyl ether (EGDE) is used as crosslinking agent, since they are already used for the preparation of biomaterials applied in humans, in particular hydrogels of hyaluronan for intradermal, intra-articular or intra-ocular administration.
- the crosslinking agent is divinyl sulfone.
- crosslinking takes place at the appropriate pH, depending on the crosslinking agent and the types of bonds being considered.
- the crosslinking is carried out in alkaline aqueous phase, for example in the presence of a solution of sodium hydroxide (NaOH).
- concentration of carboxyalkyl chitosan initially present in the aqueous phase is in the range from 1 to 30%, and preferably from 5 to 20% (m/v) by mass of carboxyalkyl chitosan relative to the volume of alkaline aqueous phase.
- the quantity of crosslinking agent is from 0.001 mol to 0.1 mol of BDDE per gram of the polymer(s).
- the amount of crosslinking agent is 0.005 to 0.02 moles per gram of polymer when using BDDE.
- the crosslinking takes place at a temperature and a duration to be adapted on a case-by-case basis, depending on the crosslinking agent, the polymers and the targeted biomechanical properties.
- crosslinking is followed by neutralization of the medium, for example by adding an acid, and for example by adding acetic acid or hydrochloric acid.
- the method comprises purification of the crosslinked beads.
- Purification makes it possible on the one hand to substantially eliminate excess coagulation agent and unreacted crosslinking agent, and on the other hand to balance the hydrogel of the beads in terms of pH and d. osmolality with the selected medium, for example a physiologically acceptable medium, such as for example a buffer solution.
- the purification comprises one or more washes with a solution comprising a buffering agent, preferably a phosphate buffered saline (often abbreviated as PBS) or the medium in which it is desired to include the beads depending on the product in question.
- a buffering agent preferably a phosphate buffered saline (often abbreviated as PBS) or the medium in which it is desired to include the beads depending on the product in question.
- the purification comprises one or more washes with pharmaceutical grade water then with a physiological solution, that is to say a solution whose pH and osmolality are suitable for injection or implantation in a tissue.
- a physiological solution that is to say a solution whose pH and osmolality are suitable for injection or implantation in a tissue.
- the purification is carried out by successive filtration/washing steps on a filter membrane or by dialysis using the selected solution and an appropriate cut-off dialysis membrane.
- the hydrogel beads are first neutralized by adding hydrochloric acid; then collected on a vacuum membrane filter. This operation can be repeated several times.
- the beads can then be suspended in a buffer solution (of composition, osmolality and pH chosen according to the indication), and collected by filtration according to a conventional technique. This step is repeated until a suspension of hydrogel beads is obtained with the osmolality and pH of the desired buffer, and a residue content in the beads below the limits specified beforehand for the targeted product, in relation to the quantity administered and its indication.
- a buffer solution of composition, osmolality and pH chosen according to the indication
- the coagulation agent content is determined according to the European Pharmacopoeia total ash method in the case of calcium chloride.
- the crosslinking agent content is determined by LC-MS in the case of BDDE, according to a method as described by Fidalgo et al. (Detection of a new reaction by-product in BDE cross-linked autoclaved hyaluronic acid hydrogels by LC-MS analysis, Medical Devices: Evidence Res 11, 367, 2018).
- the plurality of balls is classified to select balls according to their dimensions.
- the small-sized balls are eliminated, leaving the larger-sized balls to settle.
- the hydrogel beads obtained are preserved by incorporating them into an aqueous solution, for example a buffered solution such as saline phosphate buffer or any other aqueous solution, until their final formulation, sterilization and packaging.
- an aqueous solution for example a buffered solution such as saline phosphate buffer or any other aqueous solution, until their final formulation, sterilization and packaging.
- the hydrogel beads obtained are dehydrated, for example by freeze-drying or drying in a vacuum oven, and stored dry.
- the process for preparing the beads according to the invention comprises:
- a method according to the present invention comprises: - the preparation of a solution of carboxyalkyl chitosan (and optionally of another polymer, and preferably a hyaluronan) and of 1,4 butanediol diglycidyl ether (BDDE) in a basic solution containing NaOH; then
- the solution is dispersed in droplets in a coagulation bath comprising a coagulation agent, typically calcium chloride in a water/ethanol mixture, at room temperature, which causes them to coagulate in the form of spherical beads; then
- Beads are thus obtained in the form of a hydrogel comprising a matrix according to the invention.
- a matrix according to the invention is sterile.
- hydrogel in the form of beads from a matrix according to the invention according to this method.
- the composition of the invention may also comprise a polymer other than the crosslinked carboxyalkyl chitosan, in particular in the phase associated with the beads.
- the aqueous phase and/or the beads comprise one or more polymers.
- the polymer (of the associated phase and/or of the beads) is a biopolymer, for example a polysaccharide, oxidized or not, crosslinked by covalent bonds or not, for example a glycosaminoglycan, and in particular a hyaluronan such as for example sodium hyaluronate or one of its derivatives.
- the phase associated with the hydrogel beads also comprises a crosslinked or non-crosslinked carboxyalkyl chitosan.
- the plurality of beads is associated with an aqueous phase, a lipophilic phase, a hydrolipidic phase, or a solid phase, optionally comprising one or more polymers, for example a carboxyalkyl chitosan, a hyaluronan, or any combination thereof.
- the aqueous phase composition and/or the beads are in the form of a hydrogel at pH and osmolality in equilibrium with a physiological medium.
- the phase with which the beads are associated is specific to injection into a human or animal body.
- the aqueous phase and/or the beads are in a form suitable for injection into a human or animal body.
- the invention also relates to a composition which can be administered to humans or animals, said composition comprising a plurality of beads as defined according to the invention.
- the hydrogel beads according to the invention are formulated in the form of a dispersion or suspension in an injectable aqueous medium (optionally slightly viscous) in humans or animals.
- an injectable aqueous medium optionally slightly viscous
- the composition is formulated as an injectable suspension, suitable for instillation or implantable in humans or animals.
- the beads are incorporated into a solution of one or more hydrophilic biopolymers, preferably a hyaluronan.
- the formulation of beads is packaged in a device suitable for administration, for example a syringe, then sterilized in an appropriate manner, for example by autoclave, by applying a cycle intended to ensure sterility.
- the invention thus relates to sterile syringes containing formulations of hydrogel beads based on cross-linked carboxyalkyl chitosan, ready for administration by injection.
- the mass ratio [carboxyalkyl chitosan/hyaluronan] is for example from 5/95 to 95/5, for example from 10/90 to 90/10, for example from 20/80 to 80/20 and again for example from 30/70 at 70/30. According to a variant, the mass ratio [carboxyalkyl chitosan/hyaluronan] is 1/1 (ie 50% chitosan and 50% hyaluronan).
- the aqueous medium can be water, an aqueous solution, the pH and osmolality of which are for example adjusted using a buffer solution with the addition of salts and/or optionally polyols, for example sorbitol, mannitol , glycerol and/or trehalose.
- the composition of the matrix has an osmolality of 100 to 700 mosm/kg, preferably of 120 to 500 mosm/kg.
- the composition of the matrix has an osmolality of 100 to 500 mosm/kg, preferably of 120 to 270 mosm/kg.
- the osmolality of the composition of the matrix is between 250 and 400 mosm/kg, and preferably 280 to 350 mOsm/kg.
- the matrix composition has an osmolality appropriate for a joint.
- the composition of the matrix has an osmolality compatible with an ocular or intraocular surface.
- the composition of the matrix has an osmolality compatible with the dermis and the hypodermis.
- the osmolality of the composition of the matrix be between 100 and 400, and more specifically between 120 and 350 mosm/kg.
- composition according to the invention is sterile.
- the composition according to the invention is contained in an injection, implantation or instillation device such as, for example, a syringe or a vial.
- the injection device such as for example a syringe
- steam sterilization can then be packaged, preferably aseptically or sterile. It can also be a bag, a flap, or a bottle allowing the instillation of the composition according to the invention, filled aseptically after sterilization of the formulation, or directly sterilized after filling.
- a composition according to the invention is sterilized by filtration and/or by steam sterilization, before filling an injection device, with implantation or instillation, such as a syringe or a vial.
- the present invention relates more particularly to an injectable composition comprising hydrogel beads according to the invention.
- the invention also relates to a pharmaceutical composition comprising at least hydrogel beads according to the invention.
- the composition according to the invention is used as an injectable, implantable or suitable for instillation pharmaceutical composition, or an injectable or implantable or suitable for instillation medical device.
- the invention also covers a composition according to the invention in a dry form, in particular in a freeze-dried form. It is possible in particular to (re)disperse the freeze-dried product before use.
- the present invention relates more particularly to a composition according to the invention for use for therapeutic treatment, for example comprising injection by subcutaneous, intradermal, intraocular, or intra-articular, intra-mucosal, intra-peritoneal, intra -muscular of said composition, for example for the repair, regeneration or filling of at least one tissue / bodily fluid requiring repair or filling.
- biomechanical properties sought by the composition according to the invention can vary in nature and in amplitude according to the indication, for example according to the tissue in which the hydrogel must be integrated, the mechanism of action or the effect intended to ensure the benefit to the patient, and duration of effect.
- the properties of the composition according to the invention and in particular of the hydrogel beads according to the invention are adapted to the indication.
- the invention relates to hydrogel beads according to the invention which are elastic, in particular when it is necessary to ensure a lasting increase in volume at the cutaneous, hypodermic (subcutaneous) or periosteal level.
- the invention relates in particular to beads suspended in a continuous phase. This phase may also have a variable viscoelasticity, or other advantageous properties for the targeted product, for example a lubricating effect. In particular for a product for intra-articular use, this allows both shock absorption and a cartilage lubricating effect.
- a composition of the invention may have a variable level of elasticity, adjusted according to the indication, and which can be characterized by measuring the modulus of elasticity by rheometry.
- the present invention also relates to compositions comprising a phase comprising a plurality of hydrogel beads according to the invention. We can say that the balls are incorporated in this phase.
- the phase comprising the beads is an aqueous phase.
- the phase comprising the beads is a lipophilic phase.
- the phase comprising the beads is a hydrolipidic phase, and in particular an emulsion, such as for example direct, inverse, simple, multiple, etc...
- the phase comprising the beads is a solid phase.
- the phase comprising the beads is a continuous aqueous phase.
- the present invention relates to an injectable composition characterized in that it comprises hydrogel beads according to the invention and a phase in which the beads are incorporated.
- the present invention relates to a pharmaceutical composition comprising hydrogel beads according to the invention.
- composition is formulated as a pharmaceutical composition or composition for use in a therapeutic treatment method.
- the composition is used as an injectable, implantable or suitable for instillation or topical administration pharmaceutical composition, or an injectable or implantable or suitable for instillation or topical administration medical device, for example for use in a method of therapeutic treatment, for example comprising instillation or topical administration or injection by subcutaneous, intradermal, mucosal, ocular, intraocular, or intra-articular route, of said composition, for example for the repair or filling of at least one body tissue requiring repair or filling.
- the composition according to the invention is used in a method for the treatment, repair or filling of at least one liquid or body tissue requiring repair or filling, and for example the body tissue of which is chosen from the tissues belonging to the vocal cords, muscles, ligaments, tendons, mucous membranes, sexual organs, bones, joints, eyes, dermis, or any combination thereof, and more particularly the dermis, the cartilage, the synovial membrane, a wound skin or the ocular surface.
- the present invention relates to a composition according to the invention for use in a method for treating osteoarthritis, or repairing a cartilage defect, for example by injection into a biological fluid, for example synovial fluid, or after mixing with a biological fluid, for example blood, and implantation in the cartilage.
- biological fluid is meant a fluid of bodily origin which may or may not have undergone a treatment modifying its composition.
- the present invention relates to a medical device, for example a medical implant, characterized in that it comprises or consists of a composition as defined according to the invention.
- the present invention relates in particular to a composition according to the invention for use for a treatment in therapy, in surgery, or in cosmetics, including in particular a treatment in rheumatology, in ophthalmology, in gynecology, in aesthetic medicine, in plastic surgery, in internal, orthopedic and gynecological surgery, for the prevention of post-surgical tissue adhesions, in dermatology.
- the present invention also relates to a composition according to the invention for ophthalmic use, for example for a therapeutic treatment of a dry eye syndrome, of a corneal lesion, or for intraocular administration in any other ocular tissue. .
- the present invention further relates to the application of a composition according to the invention by instillation on the ocular surface to prevent or fight against a corneal lesion, or dry eye syndrome, in particular for the purpose of lubricating or regenerating the ocular surface.
- the invention also relates to a composition of eye drops comprising a carboxyalkyl chitosan defined according to the present invention.
- the subject is affected by an inflammatory pathology of the joints (e.g. osteoarthrosis, arthritis, etc.).
- an inflammatory pathology of the joints e.g. osteoarthrosis, arthritis, etc.
- the present invention relates more particularly to a composition according to the invention for the treatment of osteoarthritis, arthritis, or the repair of a cartilage defect, for example by injection into the synovial cavity or by implantation at the level of the defect. of cartilage.
- the present invention relates more particularly to a medical device, for example a medical implant, characterized in that it comprises or consists of a composition according to the invention.
- the invention therefore relates to a medical device comprising a chamber containing a composition according to the invention in a form dry, in particular in a freeze-dried form, and optionally one or more other chambers containing one or more active products, additives or excipients.
- composition according to the present invention may also comprise one or more active agents for a desired indication, and/or one or more additives or excipients making it possible to modulate the properties of the composition according to the invention.
- the beads according to the invention comprise, or in other words encapsulate, one or more active agents for a desired indication, and/or one or more additives or excipients making it possible to modulate the properties of the composition according to the invention.
- active agents for a desired indication
- additives or excipients making it possible to modulate the properties of the composition according to the invention.
- They may, for example, be active pharmaceutical ingredients or nutrients for the administration zone and in particular for the injection, instillation or implantation zone.
- the present invention also relates to a composition according to the invention formulated as a pharmaceutical composition or composition for use in a method of therapeutic treatment.
- the present invention also relates to a composition according to the invention for the preparation of a pharmaceutical composition or a medical device.
- the present invention also relates to a composition according to the invention for its use in a method for treating osteoarthritis, or repairing a cartilage defect, for example by injection into the synovial pocket or after mixing with blood and implantation in cartilage/bone.
- the present invention also relates to a composition according to the invention for use in a method of treatment or aesthetic care by filling the skin tissue.
- This notably involves, for example, injecting a composition according to the invention subcutaneously, intradermally, intramucosally or intramuscularly.
- the present invention also relates to a composition according to the invention for use in a method for treating the skin by multiple injection intradermally, or other tissues.
- Such compositions can typically be used in dermatology, as treatments for aesthetic purposes.
- the present invention also relates to a composition according to the invention for use in a method of treatment in which the composition is a viscosupplementation agent.
- the present invention also relates to a composition according to the invention for use as a cell vector, of one or more cell types, and/or vector of one or more active agents.
- They can be active agents from a point of view pharmaceutical or biological.
- the composition of the invention may indeed be compatible with the presence of cells, preferably living cells. Among the living cells of interest, mention may be made, for example: chondrocytes (articular cartilage), fibrochondrocytes (meniscus), ligament fibroblasts (ligament), skin fibroblasts (skin), tenocytes (tendons), myofibroblasts (muscle), mesenchymal stem cells, red blood cells (blood) and keratinocytes (skin).
- the composition of the invention can also be used as a therapeutic vector for the targeted, local and/or controlled-release delivery of at least one therapeutic agent.
- the beads according to the invention comprise one or more active agents, for example a water-soluble molecule (totally or partially) and/or or a water-insoluble molecule.
- the beads according to the invention comprise one or more anti-inflammatory molecules, for example a corticosteroid, in particular a glucocorticoid.
- a corticosteroid in particular a glucocorticoid.
- a water-soluble molecule is ascorbic acid.
- Another example of a water-soluble active agent is dexamethasone, an anti-inflammatory agent.
- An example of a water-insoluble active agent is triamcinolone, also an anti-inflammatory agent.
- the active agent encapsulated in the beads is a water-soluble biomolecule of high molecular mass (for example greater than 10 kDa), and for example a protein.
- the mechanism and release of the active agent will depend on its solubility profile, either by diffusion if it is water-soluble, or by degradation of the beads, for example hydrolytic or mechanical degradation.
- composition and the beads according to the present invention provide a system with local and controlled release of one or more active agents.
- the polymer composition of the beads according to the invention can be adapted to the target release profile (which depends on the indication and the molecule) and therefore allows it real versatility to adapt to encapsulation and release of different active agents.
- blood, or plasma, or a platelet lysate, or plasma rich in platelets, or any biological fluid is added with the composition of the invention making it possible, for example, to increase the performance of the product.
- the composition according to the invention is formulated in a solid form, for example a film, a tube or a porous foam, which can release the beads once administered.
- the composition is formulated in the form of a nebulizable (spray) composition.
- the present invention also relates to a composition according to the invention for use in a method for the treatment or aesthetic care of one or more tissues or organs affected by an excessive temperature, such as in the case of a burn.
- the present invention also relates to a composition according to the invention for use in a method of treatment for the repair of cartilage (for example by implantation on a cartilage defect in order to promote its regeneration).
- the invention relates to a physiologically acceptable composition, administered topically, by injection, instillation or by implantation, intended to come into contact with one or more living tissues subjected to oxidative stress, for example:
- intra-articular injection for the treatment of osteoarthritis (via synovial fluid supplementation, cartilage lubrication, shock absorption at the joint level, regeneration of the synovial membrane); intra-articular implantation to promote the repair of cartilage defects;
- -hypodermic, subcutaneous and/or periosteal injection for filling or regenerating the skin or hair follicles, for increasing volume in the event of lipoatrophy, or for the administration of active substances;
- -intraocular injection for example for optimizing the effectiveness of glaucoma surgery or vitreous supplementation, as an adjunct to ophthalmic surgeries, for the regeneration of anterior or posterior ocular tissues, and/or for the intraocular administration of active ingredients;
- vulvar mucosa for the treatment of vulvodynia.
- for cell culture as a support or scaffold for cells, in particular in a bioreactor, for example for tissue engineering or reconstruction or for the production of substances of interest by cells.
- the present invention also relates to a composition according to the invention forming an intra-articular viscosupplement.
- the ranges of osmolality and pH values of the composition are suitable, and in general close to the osmolality and pH values of the tissues in contact with the composition according to the invention.
- the composition according to the present invention is sterile.
- the composition according to the present invention is sterilized with moist heat.
- compositions of the invention are transparent or translucent.
- the invention relates in particular to articles or packaging, preferably sterile, comprising one or more instillation or injection devices pre-filled with a composition according to the invention, in particular in the form of a hydrogel). These are typically devices for instilling the product in the form of drops or pre-filled syringes.
- composition of the invention can be stored, preferably in an article or packaging appropriate to its indication, and preferably for several months.
- composition and the beads according to the invention can advantageously be sterilized.
- the invention relates to a sterilized cross-linked carboxyalkyl chitosan.
- the crosslinked carboxyalkyl chitosan is therefore thus sterile, in particular for applications requiring it.
- the beads or the composition of the invention are sterilized by steam, according to a method known to those skilled in the art and/or recommended by the European Pharmacopoeia.
- the composition can be sterilized by filtration using filters provided for this purpose, for example filters with a porosity of less than or equal to 0.2 ⁇ m.
- the present invention also covers a method of therapeutic treatment comprising the injection of a composition according to the invention.
- the present invention also covers the use of a composition according to the invention for the preparation of a pharmaceutical composition, in particular for a therapeutic treatment, for example as defined more specifically by the invention.
- the present invention also covers a method of aesthetic care, in other words non-therapeutic, comprising the injection of a composition according to the invention. This involves, for example, the treatment of lipoatrophy, or the filling of one or more areas of visible tissue damaged, for example following an accident or a surgical operation, for aesthetic purposes.
- a tissue is a set of similar cells of the same origin, grouped together as a functional set, that is to say contributing to the same function.
- tissue mention may be made of: dermal tissue (for example epithelial tissue), connective tissue, muscle tissue, adipose tissue, and nervous tissue.
- composition according to the invention or equivalent terms means a composition defined as in the present invention, including according to any one of the variants, particular or specific embodiments, independently or according to any one of their combinations, including according to the preferred characteristics.
- the measurements are carried out using a compression bench (Inston 5566, Mecmesin) equipped with a load cell (Instron 500N, Mecmesin) and a sample holder suitable for syringes.
- a 1 mL BD glass syringe containing the formulation to be tested is brought to room temperature.
- a 27G needle (V2" length, TSK) is connected to the syringe and the syringe is placed in the sample holder.
- homogeneous gel/phase is collected on a watch glass.
- the ejection force is determined as being the average value of the plateau of the force-displacement curve at constant speed.
- the integrity of the beads is then checked after ejection by optical microscopy ( shape, surface).
- Images of the beads are recorded using the Olympus CKX-41 microscope equipped with an Olympus SC-50 camera and Olympus Stream image image capture software, then processed using the CellSens Dimension Desktop software. For this, one or two drops of a suspension of the beads are placed on a borosilicate glass slide, and covered with an object lid. The slide is immediately placed on the microscope stage.
- a magnification of 4x is chosen to visualize at least 20 beads per image.
- Ten images are recorded, then analyzed with the CellSens software to determine the dimensions of the beads (width, length, diameter).
- the sphericity of a ball is equal to the square quotient of its width over its length. The final value reported is the average of the measurements for each sample after analysis of 10 images (minimum of 200 beads in total).
- a perfectly spherical ball has a sphericity equal to 1.
- a quantity of approximately 500mg of hydrated beads is placed on a paper to remove excess unbound water.
- the beads are placed on the pan of a Moisture Analyzer MA37 (Sartorius) moisture balance and dried, according to the method of the European Pharmacopoeia 2.2.32.
- the water content is calculated as the difference between the wet mass and the dry mass.
- the ash content reflects the ability to remove excess mineral substances during the washing steps, mainly calcium chloride during the coagulation step.
- the measurement is carried out by calcination at 600° C., according to the European Pharmacopoeia method 2.4.16 (Total ashes), on the beads previously dehydrated in a vacuum study and whose water content has been measured beforehand.
- the ash content is related to the mass of dry balls.
- Unreacted BDDE crosslinker may be found in its native form or as a by-product.
- concentration of BDDE or its residual by-product is determined by LC-MS according to a method adapted from that of Fidalgo et al. (Detection of a new reaction by-production BDDE cross-linked autoclaved hyaluronic acid hydrogels by LC-MS analysis, Medical Devices: Evidence Res 11, 367, 2018).
- a maximum limit of 2ppm of BDDE and its by-product cumulative content
- the laser diffractometry measurements are carried out using a Mastersizer 2000 (Malvern) equipped with a “hydro-unit” (Hydro 2000SM).
- a volume of the suspension of beads to be tested is introduced into the hydro-unit containing pharmaceutical grade water using a pipette, until a level of obscuration between 3% and 10% is obtained, an obscuration titration being carried out beforehand in order to determine the optimum level of obscuration.
- the hydro-unit is agitated at a speed that ensures even dispersion of the sample and the absence of bubbles in the system.
- the optical parameters (refractive index) used are 1.52 for the sample (suspension of beads) and 1.33 for the water. Each measurement is performed in triplicate.
- the cast of ball size (in diameter) is calculated and provided by the equipment (average of the 3 measurements).
- the equipment calculates the size distribution of the balls and the software is configured to obtain the following data: average diameter by volume, diameter at 10% (D0.1), 50% (D0.5) and 90% (DO, 9 ) of volume distribution.
- the biomechanical profile of the bead suspensions in their continuous phase is characterized using a DHR-2 Hydrid Rheometer (TA Instrument) equipped with a 20 mm planar geometry spaced 700 ⁇ m with a Peltier, at a temperature of 37°C, a frequency of 0.7 Hz and a deformation amplitude ranging from 0.1 to 1000%.
- the equipment provides the values of the modulus of elasticity (G'). Each measurement being carried out in triplicate, the average value of the G' of the 3 measurements is calculated.
- a support has been specially designed to be able to immobilize the suspension of beads during analysis by confocal laser scanning microscopy. It is a disc based on a biomaterial of the hydrated polyacrylate type (as described in patent WO 2006063994), comprising a well in which the beads are deposited. The beads are analyzed in suspension in saline phosphate buffer. One to two drops of the suspension of the beads are placed, then the measurements are carried out using the confocal laser scanning microscope VK-X (Keyence), at a magnification of 20.
- the images beads are compared with an image of the surface of a 'mirror polished' polyacrylate slide taken as a “very smooth” control and with an image of freeze-dried beads taken as a “very rough” control.
- carboxymethyl chitosan (CO) references CC1, CC2 and CC3 of the examples
- carboxymethylation reaction of the chitosan is carried out according to the method next.
- a mass of 30g of chitosan of Agaricus bisporus origin is dispersed in 600mL of isopropanol, 41 mL of water and 163mL of sodium hydroxide at 50% (m/v).
- a mass of 135 g of monochloroacetic acid (MCA) is dissolved in isopropanol, and the solution is added to the suspension of chitosan.
- MCA monochloroacetic acid
- the polymer is recovered by precipitation in ethanol, then purified by cycles of solubilization in water and precipitation in ethanol.
- the CC is collected after drying.
- a step is added according to the following method.
- a mass of 21 g of CC from step 1 is dispersed in 570mL of water, and the pH of the solution is adjusted to pH approximately 8.
- a volume of 10mL of acetic anhydride is added, and the solution is stirred at room temperature.
- the pH of the solution is adjusted then a volume of 10mL of acid anhydride is added.
- the pH is adjusted to approximately 7.0 - 7.5.
- the CC is collected after drying.
- CC beads it is sought to form CC beads using a process consisting of first coagulating drops of the polymer with calcium chloride, by ionic gelation, then stabilizing them by covalent crosslinking by adding a cross-linking agent, 1,4 butanediol diglycidyl ether (BDDE, Alfa Aesar, CAS [2425-79-8]).
- BDDE 1,4 butanediol diglycidyl ether
- 3 reference CC solutions CC2 (Table 1) are prepared in water, at a concentration of 40mg/mL.
- the pH of the solutions is adjusted to 3, 6 or 13 by adding either 1N hydrochloric acid and/or 1N sodium hydroxide to the desired pH, diluted to 30mg/mL by adding water and filled into a 1 mL syringe.
- a solution of calcium chloride with a concentration of 30 mg/mL in a 30/70 (v/v) ethanol/water mixture is prepared.
- droplets are formed by slowly ejecting the CC solution through a 27G (2mL) needle.
- the drops fall into the calcium chloride solution (10mL), which coagulates them in the form of gelled beads.
- the beads are left in suspension in the calcium chloride solution for 1 hour, then 80 ⁇ l of BDDE (BDDE/CC ratio of 1.33 ⁇ l/mg) are added.
- the mixture is left stirring for 1 hour, then the beads are collected on a filter membrane.
- the beads are washed by resuspending them in water and filtering them to remove excess calcium chloride and unreacted BDDE. This step is repeated 3 more times, then the beads are suspended in water for 1 hour.
- Example 2 Hydrogel beads based on carboxymethyl chitosan (CC)
- the objective of this example was to provide crosslinked CC hydrogel beads according to the invention, which are spherical (sphericity greater than 0.70), smooth, resistant to compression, with a diameter of between approximately 20 ⁇ m and 400 ⁇ m and whose mass water content is greater than 85%. It is evaluated whether the beads can be washed in an aqueous medium to purify and balance them in terms of pH and osmolality. We also try to sort the balls according to their diameter.
- the beads are produced according to the following general method, with the specific conditions and parameters reported in Table 3. Then, the beads can be dispersed in a continuous phase, and the mixture is packaged and possibly sterilized according to the specifications of the targeted product, for example as described in Example 3.
- the beads can alternatively be dried, for example by freeze-drying or any other appropriate drying method, and packaged in dry form.
- a solution of CC1 (Table 1) (30 mg/mL) in a 1% NaOH solution is prepared and the BDDE is added thereto in a proportion of 3 ⁇ L (0.0162 mmol) per mg of CC.
- This solution is dispersed in droplets using a nebulizer (mini-Büchi) via a binary nozzle with a diameter of 2.8 mm, at an air pressure of 0.3 bar.
- the droplets fall into a coagulation bath based on calcium chloride (50mg/mL) in a 30/70 (v/v) water/ethanol mixture, at room temperature, which causes them to coagulate in the form of spherical beads.
- the suspension is then neutralized by adding a 1N hydrochloric acid solution, the beads are collected on a membrane filter under vacuum, they are resuspended in hydrochloric acid and then they are collected on the membrane filter. They are suspended in the saline phosphate buffer, they are collected by filtration, then this step is repeated until a suspension of gel beads with the osmolality and pH of the buffer is obtained.
- the gel beads are sorted according to their size by placing them on a sieve with a porosity of 400 ⁇ m then by vacuum filtration with filters of decreasing porosity. 3 fractions of hydrogel beads with references SB2-A, B and C are thus obtained, which are kept in suspension in a saline phosphate buffer.
- the 3 bead fractions are characterized according to the methods as detailed in the description: size distribution by laser diffractometry (Mastersizer 2000, Malvern); water content using a moisture balance (Moisture Analyzer MA37, Sartorius); compressive strength by a qualitative method (with a mass weight of 50g); sphericity and visual inspection by optical microscopy; surface roughness by scanning confocal microscopy. The results are reported in Table 4.
- fractions of CC hydrogel beads of reference SB2-A or SB2-B of Example 2 are collected and then mixed with a solution of sodium hyaluronate (reference HA2 of Table 2) at 2% (m/m) in a saline phosphate buffer, in a mass proportion of 70/30, in order to obtain two separate formulations.
- a solution of sodium hyaluronate reference HA2 of Table 2
- the formulations are gently agitated for approximately 12 hours at room temperature. Then, they are packaged in 1 mL glass syringes (Hypak, BD), which are closed with a cap (Hypak, BD). The syringes are placed in an autoclave (Systec, DX65). Sterile syringes of the two formulations of CC hydrogel beads ready for administration by injection are thus obtained (references FSB1 -A and FSB1 - B).
- the final formulations are characterized (pH, osmolality, residual BDDE content, modulus of elasticity G', ease of ejection of the composition through a fine needle of 27G (TSK, 1/2”). the balls to check that they are not altered by the process (shape, surface, compressive strength).
- CC hydrogel beads according to the invention can be formulated in an HA solution then packaged and sterilized in a 1 mL syringe without being altered, because they retain their homogeneity, their spherical shape, their smooth surface and their compressive strength.
- Both FSB2-A and B formulations are consistent in terms of pH balance and osmolality with the aqueous phase used. They are compliant in terms of residual BDDE content and BDDE by-product ( ⁇ 2ppm).
- the formulations are easily injected via a 27G needle, requiring a force of 9 to 10N for their ejection into the air, quite satisfactory especially for hypodermic injection.
- the beads retain their integrity after ejection, as verified by visual inspection by light microscopy.
- the formulations would therefore be suitable for an indication of skin volumization for aesthetic purposes, in particular by injection into the hypodermis.
- hyaluronan is added, in the form of sodium hyaluronate, (reference HA1 of Table 2) to a solution of CC (reference CC2 of Table 1) and of BDDE.
- CC/HA mass ratios 50/50 and 75/25) are used, for the same total polymer concentration of 40 mg/mL. It is sought to form balls with a diameter between 10 ⁇ m and 400 ⁇ m, approximately. The same general method as in Example 2 is applied, with parameters adjusted as described in Table 6.
- Resistant beads are indeed obtained at the end of the purification, formulation and sterilization steps.
- the characteristics of the beads as well as the final sterile formulations are given in Table 7.
- CC and HA beads were obtained, the water content of which is increased (93% and 97%) compared to the CC beads alone of Example 1 (90%). They are more deformable, more elastic and more sticky than the balls of Example 1.
- CC hydrogel beads can be modulated by modifying the composition of the polymer solution, for example by adding HA in variable proportions.
- the same general method could be applied, with an adaptation of certain parameters.
- hydrogel beads from a CC of Agaricus bisporus origin whose DA is less than 30% (reference CC3 of Table 1), according to the same general method as in Example 2 by adjusting the parameters (Table 8).
- the droplets are formed by passing the polymer solution through a 30G needle instead of the atomization process of Examples 2 to 3. Consequently, the beads will have a larger diameter than those of Examples 1 to 3 (in the order of mm). Nevertheless, this process makes it possible to judge the conformity of the beads in terms of sphericity, smooth surface and good resistance to manual compression after the washing steps.
- CC hydrogel beads are evaluated after injection into the hypodermis (subcutaneously) in rats, for a period of 3 months.
- the two formulations based on CC hydrogel beads of Example 3, ready for injection, are used: FSB2-A (average diameter by volume 90 ⁇ m) and FSB2-B (average diameter by volume 200 ⁇ m).
- Ellansé-M (Sinclair Pharma), based on solid and non-hydrated microspheres of polycaprolactone in a carboxymethyl cellulose gel
- Restylane® LYFT (Galderma), cross-linked hyaluronic acid hydrogel extruded in the form of non-spherical particles.
- particles is used in this example to refer to both CC hydrogel beads, solid polycaprolactone microspheres and extruded cross-linked hyaluronic acid particles.
- the erythema and edema scores are negative throughout the first week for the 4 products tested. They remain harmed throughout the 3-month observation period. No clinical sign of skin irritation reaction is therefore observed for any of the 4 products tested, and their local tolerance is considered excellent.
- the volumizing effect of the commercial product Ellansé-M is characterized by a high volume relief during the first two weeks, which then stabilizes at the same level as that of the 2 products based on CC hydrogel beads until the end of the study.
- the average volume of the relief created by the commercial product Restylane® LYFT is initially of the same order of magnitude as the other products during the first 2 weeks. Thereafter, it is significantly lower at all time points due to its gradual decrease from day 14 until the end of the study (day 85).
- CC's hydrogel beads thus confirm their safety and efficacy as a tissue volumizing product, in particular for the skin.
- the local reaction, including inflammatory and foreign body reaction, of the two formulations FSB2-A and B is characterized by histopathological analysis of the skin tissue at the injection sites of the study of Example 6, at the delays of 1 month and 3 months after injection. The procedure is the same for the tissues of the injection sites of the two reference commercial products.
- the local reaction is proceeding adequately for the products based on hydrogel particles (CC beads and Restylane® LYFT), with “null to low” score responses for all parameters.
- the cellular response has not changed or has decreased, and tissue invasion is observed within the CC hydrogel beads (but not Restylane particles).
- a greater cellular reaction is noted at 1 month, with a “moderate to marked” score for macrophages and higher scores than the other products for lymphocytes and giant cells. The presence of necrosis is observed for one of the sites.
- the reaction remains significant at 3 months, a sign of a recurrent inflammatory response characterized by the persistence of lymphocytes, macrophages (“moderate to marked” score) and giant cells, at ever higher scores than for the other products.
- a model molecule (here water-soluble), ascorbic acid, is incorporated into the preformed CC hydrogel beads in order to demonstrate their ability to act as a reservoir for substances, for example active principles, nutrients, etc. .
- the reference beads SB2-C average diameter by volume 373 ⁇ m) of Example 2, collected beforehand in their hydrated form, are used.
- the balls are put in suspension in a solution of ascorbic acid with a concentration of 50 mg/ml in saline phosphate buffer, then slight agitation is applied for 12 hours at ambient temperature.
- the beads are then separated from the solution by filtration under vacuum on a membrane, and suspended in the saline phosphate buffer for 7 days.
- a fraction of the beads are characterized by FTIR, after having rinsed them by washing with the buffer and dehydrated by freeze-drying.
- the SB2-C beads suspended in the same buffer but without ascorbic acid are subjected to the same process, and their FTIR spectrum is recorded.
- the FTIR spectra of the beads suspended in the ascorbic acid solution show two additional bands at 862 cm 1 and 530 cm 1 compared to the spectra of the beads suspended in the buffer alone, which confirms the presence of ascorbic acid in the CC balls.
- the CC hydrogel beads are capable of acting as a reservoir for a water-soluble molecule such as ascorbic acid, incorporating them via a process of simple diffusion of ascorbic acid to the preformed beads.
- a water-soluble molecule such as ascorbic acid
- the encapsulation process makes it possible to encapsulate triamcinolone without altering it.
- the balls contain at least 80% water, are spherical and resistant to compression. Being water-insoluble, the triamcinolone is dispersed in the hydrogel of the beads. Triamcinolone powder has particles with a diameter between 1 ⁇ m and 10 ⁇ m, which are therefore visible to the naked eye, which is acceptable because a smooth surface and transparency of the beads are not required for local administration applications. .
- the triamcinolone is placed in suspension with the initial solution of the polymer(s) (references CC1 and HA1 of Tables 1 and 2) from the first stage of bead preparation. Then, the beads are formed according to the general method of Examples 2 and 4, starting from a solution comprising the polymer(s), the triamcinolone and the crosslinking agent (BDDE). The balls are collected, without splitting them according to their size. The beads are characterized according to the methods described in the preceding examples (Table 12). The triamcinolone content in the beads is evaluated using the following method: A quantity of beads is introduced into centrifugation tubes and suspended in an ethanol/water solution (30:20, v/v), which allows dissolution and diffusion of the triamcinolone out of the beads.
- the suspension is centrifuged at 2500 rpm for 10 minutes. Then the absorbance of the supernatant is measured at 242 nm using a spectrophotometer (Multiskan Sky High, Thermo Scientific). A calibration curve is produced under the same conditions with solutions of triamcinolone from 0 to 0.5 mg/mL. The triamcinolone content is expressed as mass of triamcinolone per mass of wet beads (Table 12).
- triamcinolone is incorporated in the form of particles dispersed within the hydrogel of the beads, which makes them opaque. It is also noted that the balls are not smooth but slightly rough, due to the presence of these particles. These two observations are consistent with the solubility profile of triamcinolone. Furthermore, the balls are in accordance with the invention in terms of water content, sphericity and resistance to compression.
- Sterile formulations are prepared with the 3 types of hydrogel and triamcinolone beads of Example 9.
- the beads are suspended in a hyaluronan solution (reference HA2 of Table 2) according to the same general method as in Example 3
- the formulations are packaged in 3 mL syringes (Hypak, BD), and sterilized by autoclave.
- the beads are sedimented by centrifugation at 600 revolutions/min for 5 minutes. 0.4 mL of supernatant is collected and 0.6 mL of ethanol is added thereto. Then the absorbance of the solution is measured at a wavelength of 242 nm via a spectrophotometer (Multiskan Sky High, Thermo Scientific). A calibration curve is produced in parallel under the same operating conditions with solutions of triamcinolone alone. The concentration of triamcinolone in the supernatant is then calculated for each delay (each tube). Finally, the cumulative quantity of triamcinolone released is calculated, expressed in mg per g of wet bead (Table 13).
- the triamcinolone is actually released outside the beads, into the supernatant, from a certain delay then gradually throughout the study. Under the conditions of this test, the release begins on the second day for the SB8-1 and SB8-2 beads. For SB8-3 balls, it starts from the seventh day. Most of the initial triamcinolone content is released on the last day of the test for the 3 types of beads, which indicates that there is no blockage of its release in an aqueous medium when the beads are placed under mechanical stress. It is concluded that triamcinolone may well be gradually released from CC or CC/HA hydrogel beads placed under mechanical stress. In addition, by varying the polymer composition of the beads, it is possible to modulate the delay for the onset of the release and the kinetics of the release. The polymer composition of the beads can be adjusted according to the release profile of the active agent used and according to the intended indication.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Composite Materials (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2012010A FR3116534B1 (en) | 2020-11-23 | 2020-11-23 | Chitosan-based beads, preparation, compositions and applications |
PCT/EP2021/082454 WO2022106676A1 (en) | 2020-11-23 | 2021-11-22 | Chitosan-based beads, and preparation, compositions and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4132980A1 true EP4132980A1 (en) | 2023-02-15 |
Family
ID=75953889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21806782.5A Pending EP4132980A1 (en) | 2020-11-23 | 2021-11-22 | Chitosan-based beads, and preparation, compositions and uses thereof |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230066712A1 (en) |
EP (1) | EP4132980A1 (en) |
JP (1) | JP2023550573A (en) |
KR (1) | KR20230109093A (en) |
CN (1) | CN115066443A (en) |
FR (1) | FR3116534B1 (en) |
WO (1) | WO2022106676A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3074043B1 (en) | 2017-11-28 | 2020-11-13 | Kiomed Pharma | ANIONIC CHARGED CHITOSAN |
FR3074044B1 (en) | 2017-11-28 | 2019-11-01 | Kiomed Pharma | CARBOXYALKYL CHITOSANE |
CN115779145A (en) * | 2022-12-20 | 2023-03-14 | 北京健康广济生物技术有限公司 | Preparation method of hyaluronic acid gel filled in face and containing chitosan microspheres |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE1014638A6 (en) | 2002-02-12 | 2004-02-03 | Univ Liege | Method of preparation of derivatives of cell wall from biomass. |
BE1016383A3 (en) | 2004-12-15 | 2006-10-03 | Physiol | Polymer composition for intraocular lens. |
FR2955258A1 (en) | 2010-01-20 | 2011-07-22 | Biopharmex Holding Ltd | INJECTABLE COMPOSITION |
CN104941601B (en) * | 2015-07-09 | 2018-07-06 | 成都理工大学 | A kind of preparation method of carboxymethyl chitosan gel ball |
FR3038837B1 (en) | 2015-07-13 | 2017-08-18 | Synolyne Pharma | CHITOSANE FOR MIXING WITH A COAGULABLE FLUID |
FR3038838B1 (en) | 2015-07-13 | 2017-08-18 | Synolyne Pharma | CHITOSANE FOR MIXING WITH A COAGULABLE FLUID |
-
2020
- 2020-11-23 FR FR2012010A patent/FR3116534B1/en active Active
-
2021
- 2021-11-22 EP EP21806782.5A patent/EP4132980A1/en active Pending
- 2021-11-22 WO PCT/EP2021/082454 patent/WO2022106676A1/en active Application Filing
- 2021-11-22 KR KR1020227022525A patent/KR20230109093A/en unknown
- 2021-11-22 CN CN202180013938.5A patent/CN115066443A/en active Pending
- 2021-11-22 JP JP2022540756A patent/JP2023550573A/en active Pending
- 2021-11-22 US US17/790,180 patent/US20230066712A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
FR3116534A1 (en) | 2022-05-27 |
CN115066443A (en) | 2022-09-16 |
JP2023550573A (en) | 2023-12-04 |
WO2022106676A1 (en) | 2022-05-27 |
US20230066712A1 (en) | 2023-03-02 |
FR3116534B1 (en) | 2023-12-22 |
KR20230109093A (en) | 2023-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4132980A1 (en) | Chitosan-based beads, and preparation, compositions and uses thereof | |
EP3976663A1 (en) | Chitosan and applications thereof | |
WO2016016463A1 (en) | Thermogelling composition | |
EP3285781B1 (en) | Homogeneous aqueous solution of injectable chitosan having a ph close to physiological ph | |
EP3156059B1 (en) | Sterilised thermogelling composition | |
WO2017009346A1 (en) | Chitosan for mixing with a coagulable fluid | |
WO2017009335A1 (en) | Chitosan for mixing with a coagulable fluid | |
EP2254584B1 (en) | Biocompatible injectable products with zinc and/or zinc-form saccharide-salt release, and uses thereof | |
EP3510051B2 (en) | Carboxyalkyl chitosan | |
EP3510050B1 (en) | Anionically charged chitosan | |
WO2022229787A1 (en) | Biocompatible product having a matrix comprising a polysaccharide co-crosslinked with chitosan | |
FR3091995A1 (en) | Chitosan gel massage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220630 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40079626 Country of ref document: HK |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |